WO2023284834A1 - 一种哌啶衍生物及其药物组合物、制备方法和用途 - Google Patents
一种哌啶衍生物及其药物组合物、制备方法和用途 Download PDFInfo
- Publication number
- WO2023284834A1 WO2023284834A1 PCT/CN2022/105776 CN2022105776W WO2023284834A1 WO 2023284834 A1 WO2023284834 A1 WO 2023284834A1 CN 2022105776 W CN2022105776 W CN 2022105776W WO 2023284834 A1 WO2023284834 A1 WO 2023284834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- substituted
- alkyl
- pharmaceutically acceptable
- hydrogen
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 150000003053 piperidines Chemical class 0.000 title abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 317
- 102000005962 receptors Human genes 0.000 claims abstract description 46
- 108020003175 receptors Proteins 0.000 claims abstract description 46
- 208000002193 Pain Diseases 0.000 claims abstract description 41
- 230000036407 pain Effects 0.000 claims abstract description 26
- 208000011117 substance-related disease Diseases 0.000 claims abstract description 22
- 108010020615 nociceptin receptor Proteins 0.000 claims abstract description 17
- PULGYDLMFSFVBL-SMFNREODSA-N nociceptin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 PULGYDLMFSFVBL-SMFNREODSA-N 0.000 claims abstract description 13
- 201000009032 substance abuse Diseases 0.000 claims abstract description 12
- 208000007848 Alcoholism Diseases 0.000 claims abstract description 11
- 108090000622 Nociceptin Proteins 0.000 claims abstract description 11
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 10
- 230000036506 anxiety Effects 0.000 claims abstract description 10
- 231100000736 substance abuse Toxicity 0.000 claims abstract description 10
- 201000006152 substance dependence Diseases 0.000 claims abstract description 10
- 102000048266 Nociceptin Human genes 0.000 claims abstract 4
- -1 N-alkylpyrrolyl Chemical group 0.000 claims description 120
- 125000000217 alkyl group Chemical group 0.000 claims description 65
- 229910052739 hydrogen Inorganic materials 0.000 claims description 53
- 239000001257 hydrogen Substances 0.000 claims description 53
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 46
- 239000000651 prodrug Chemical class 0.000 claims description 43
- 229940002612 prodrug Drugs 0.000 claims description 43
- 125000001072 heteroaryl group Chemical group 0.000 claims description 41
- 150000003839 salts Chemical class 0.000 claims description 41
- 239000002904 solvent Substances 0.000 claims description 41
- 239000002207 metabolite Chemical class 0.000 claims description 38
- 239000012453 solvate Substances 0.000 claims description 37
- 125000003545 alkoxy group Chemical group 0.000 claims description 35
- 239000000460 chlorine Substances 0.000 claims description 34
- 150000002431 hydrogen Chemical class 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 28
- 229910052801 chlorine Inorganic materials 0.000 claims description 24
- 239000011737 fluorine Substances 0.000 claims description 23
- 229910052731 fluorine Inorganic materials 0.000 claims description 23
- 102000051367 mu Opioid Receptors Human genes 0.000 claims description 23
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 23
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 20
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 19
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 102000048260 kappa Opioid Receptors Human genes 0.000 claims description 14
- 108020001588 κ-opioid receptors Proteins 0.000 claims description 14
- 241000534944 Thia Species 0.000 claims description 12
- 208000004296 neuralgia Diseases 0.000 claims description 12
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 11
- 229910052794 bromium Inorganic materials 0.000 claims description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 10
- 206010065390 Inflammatory pain Diseases 0.000 claims description 9
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- 208000000094 Chronic Pain Diseases 0.000 claims description 8
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- 208000005298 acute pain Diseases 0.000 claims description 6
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 125000003386 piperidinyl group Chemical group 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 5
- 208000004998 Abdominal Pain Diseases 0.000 claims description 5
- 208000006820 Arthralgia Diseases 0.000 claims description 5
- 206010006002 Bone pain Diseases 0.000 claims description 5
- 206010019233 Headaches Diseases 0.000 claims description 5
- 208000000112 Myalgia Diseases 0.000 claims description 5
- 208000004550 Postoperative Pain Diseases 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 231100000869 headache Toxicity 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 208000013465 muscle pain Diseases 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 5
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 125000002757 morpholinyl group Chemical group 0.000 claims description 4
- 125000004193 piperazinyl group Chemical group 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 claims description 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 125000005958 tetrahydrothienyl group Chemical group 0.000 claims description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 2
- 125000004863 4-trifluoromethoxyphenyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C([H])C([H])=C1* 0.000 claims description 2
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 claims description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- BTQZKHUEUDPRST-UHFFFAOYSA-N 1-fluoro-3-methylbenzene Chemical compound CC1=CC=CC(F)=C1 BTQZKHUEUDPRST-UHFFFAOYSA-N 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Chemical group COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 abstract description 11
- 239000003446 ligand Substances 0.000 abstract description 7
- 239000003399 opiate peptide Substances 0.000 abstract 2
- 108010011903 peptide receptors Proteins 0.000 abstract 2
- 102000014187 peptide receptors Human genes 0.000 abstract 2
- 108070000021 Opioid peptides receptors Proteins 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 description 155
- 230000015572 biosynthetic process Effects 0.000 description 140
- 239000002994 raw material Substances 0.000 description 122
- 238000006243 chemical reaction Methods 0.000 description 113
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 108
- 238000001308 synthesis method Methods 0.000 description 93
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 79
- 239000012265 solid product Substances 0.000 description 73
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 69
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 67
- 230000000202 analgesic effect Effects 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 239000000047 product Substances 0.000 description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 35
- 239000012071 phase Substances 0.000 description 35
- 238000003756 stirring Methods 0.000 description 35
- 230000000694 effects Effects 0.000 description 34
- 239000007787 solid Substances 0.000 description 34
- 101001122476 Homo sapiens Mu-type opioid receptor Proteins 0.000 description 33
- 102100028647 Mu-type opioid receptor Human genes 0.000 description 33
- 210000002683 foot Anatomy 0.000 description 31
- 239000000243 solution Substances 0.000 description 31
- 241000700159 Rattus Species 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 29
- 239000012043 crude product Substances 0.000 description 28
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 26
- 239000005457 ice water Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 21
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical compound O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 17
- 239000007864 aqueous solution Substances 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 16
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical compound C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 15
- 239000003208 petroleum Substances 0.000 description 15
- FPKISACHVIIMRA-UHFFFAOYSA-N 4-propan-2-ylcyclohexan-1-one Chemical compound CC(C)C1CCC(=O)CC1 FPKISACHVIIMRA-UHFFFAOYSA-N 0.000 description 14
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000000018 receptor agonist Substances 0.000 description 14
- 229940044601 receptor agonist Drugs 0.000 description 14
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 13
- 102000003840 Opioid Receptors Human genes 0.000 description 13
- 108090000137 Opioid Receptors Proteins 0.000 description 13
- 229910052786 argon Inorganic materials 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000012074 organic phase Substances 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 239000000556 agonist Substances 0.000 description 12
- 239000007791 liquid phase Substances 0.000 description 12
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 12
- 239000013641 positive control Substances 0.000 description 12
- 238000004237 preparative chromatography Methods 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- GAUUDQVOPUKGJD-UHFFFAOYSA-N 1-(bromomethyl)-2-chloro-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C(Cl)=C1 GAUUDQVOPUKGJD-UHFFFAOYSA-N 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 235000011114 ammonium hydroxide Nutrition 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 description 10
- 239000000706 filtrate Substances 0.000 description 10
- 239000003643 water by type Substances 0.000 description 10
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 9
- 208000000114 Pain Threshold Diseases 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 210000004209 hair Anatomy 0.000 description 9
- 230000037040 pain threshold Effects 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229940086542 triethylamine Drugs 0.000 description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000730 antalgic agent Substances 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 238000004587 chromatography analysis Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000010189 synthetic method Methods 0.000 description 8
- 206010012335 Dependence Diseases 0.000 description 7
- 102400001111 Nociceptin Human genes 0.000 description 7
- 229940035676 analgesics Drugs 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 238000010791 quenching Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- SILNNFMWIMZVEQ-UHFFFAOYSA-N 1,3-dihydrobenzimidazol-2-one Chemical compound C1=CC=C2NC(O)=NC2=C1 SILNNFMWIMZVEQ-UHFFFAOYSA-N 0.000 description 6
- PURSZYWBIQIANP-UHFFFAOYSA-N 1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC=CC=C1CBr PURSZYWBIQIANP-UHFFFAOYSA-N 0.000 description 6
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 6
- 206010038678 Respiratory depression Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 229960002870 gabapentin Drugs 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229960005181 morphine Drugs 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 239000012224 working solution Substances 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- HSVILZRSIHLKDX-UHFFFAOYSA-N 1-(bromomethyl)-4,5-dichloro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Cl)C=C1CBr HSVILZRSIHLKDX-UHFFFAOYSA-N 0.000 description 5
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 5
- 230000001270 agonistic effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 230000009977 dual effect Effects 0.000 description 5
- 239000012065 filter cake Substances 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 210000003370 receptor cell Anatomy 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 5
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 4
- KMQWNQKESAHDKD-UHFFFAOYSA-N 2-chloro-4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(Cl)=C1 KMQWNQKESAHDKD-UHFFFAOYSA-N 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 239000005909 Kieselgur Substances 0.000 description 4
- 102100028646 Nociceptin receptor Human genes 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 230000036592 analgesia Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002480 mineral oil Substances 0.000 description 4
- 235000010446 mineral oil Nutrition 0.000 description 4
- 229940005483 opioid analgesics Drugs 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 3
- CXUCKELNYMZTRT-UHFFFAOYSA-N 1-Ethyl-2-benzimidazolinone Chemical compound C1=CC=C2NC(=O)N(CC)C2=C1 CXUCKELNYMZTRT-UHFFFAOYSA-N 0.000 description 3
- WMKYKQWKLILFBM-UHFFFAOYSA-N 2h-pyridine-1-carboxylic acid Chemical compound OC(=O)N1CC=CC=C1 WMKYKQWKLILFBM-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 3
- PLUBXMRUUVWRLT-UHFFFAOYSA-N Ethyl methanesulfonate Chemical compound CCOS(C)(=O)=O PLUBXMRUUVWRLT-UHFFFAOYSA-N 0.000 description 3
- 101001122499 Homo sapiens Nociceptin receptor Proteins 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- CFYPMQOOJMKHCV-UHFFFAOYSA-N NC(C=C1Cl)=C(CN(C(C2=CC=CC=C22)=O)C2=O)C=C1Cl Chemical compound NC(C=C1Cl)=C(CN(C(C2=CC=CC=C22)=O)C2=O)C=C1Cl CFYPMQOOJMKHCV-UHFFFAOYSA-N 0.000 description 3
- HYKJKRAMKYMKMH-UHFFFAOYSA-N O=C1N(C2CCN(CC(C=CC(F)=C3)=C3Cl)CC2)C(C=C(C(Cl)=C2)Cl)=C2N1CCN1CCCC1 Chemical compound O=C1N(C2CCN(CC(C=CC(F)=C3)=C3Cl)CC2)C(C=C(C(Cl)=C2)Cl)=C2N1CCN1CCCC1 HYKJKRAMKYMKMH-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YKRPBMFMAFXQCO-UHFFFAOYSA-N [O-][N+](C(C=C1Cl)=C(CN(C(C2=CC=CC=C22)=O)C2=O)C=C1Cl)=O Chemical compound [O-][N+](C(C=C1Cl)=C(CN(C(C2=CC=CC=C22)=O)C2=O)C=C1Cl)=O YKRPBMFMAFXQCO-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical class C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- CSMVOZKEWSOFER-RQNOJGIXSA-N cebranopadol Chemical compound C1([C@]2(CC[C@@]3(CC2)C2=C(C4=CC(F)=CC=C4N2)CCO3)N(C)C)=CC=CC=C1 CSMVOZKEWSOFER-RQNOJGIXSA-N 0.000 description 3
- 229950004621 cebranopadol Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 210000004345 peroneal nerve Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- WIYWFMMXHWCDLO-UHFFFAOYSA-N tert-butyl 4-(2-amino-4,5-dichloroanilino)piperidine-1-carboxylate Chemical compound NC1=C(C=C(C(=C1)Cl)Cl)NC1CCN(CC1)C(=O)OC(C)(C)C WIYWFMMXHWCDLO-UHFFFAOYSA-N 0.000 description 3
- IWHUJZZNFWHVFI-UHFFFAOYSA-N tert-butyl 4-(4,5-dichloro-2-nitroanilino)piperidine-1-carboxylate Chemical compound ClC1=CC(=C(C=C1Cl)NC1CCN(CC1)C(=O)OC(C)(C)C)[N+](=O)[O-] IWHUJZZNFWHVFI-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000002972 tibial nerve Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 2
- HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 2
- FXOCDIKCKFOUDE-UHFFFAOYSA-N 1,2-dichloro-4-fluoro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(Cl)C=C1F FXOCDIKCKFOUDE-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- HIKRJHFHGKZKRI-UHFFFAOYSA-N 2,4,6-trimethylbenzaldehyde Chemical compound CC1=CC(C)=C(C=O)C(C)=C1 HIKRJHFHGKZKRI-UHFFFAOYSA-N 0.000 description 2
- UGHOJWLZPSTTKB-UHFFFAOYSA-N 4-(2-bromoethyl)morpholine;hydrobromide Chemical compound Br.BrCCN1CCOCC1 UGHOJWLZPSTTKB-UHFFFAOYSA-N 0.000 description 2
- VGVHNLRUAMRIEW-UHFFFAOYSA-N 4-methylcyclohexan-1-one Chemical compound CC1CCC(=O)CC1 VGVHNLRUAMRIEW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 102100033864 G-protein coupled receptor 84 Human genes 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 101001069589 Homo sapiens G-protein coupled receptor 84 Proteins 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000026251 Opioid-Related disease Diseases 0.000 description 2
- 206010033425 Pain in extremity Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 102000000072 beta-Arrestins Human genes 0.000 description 2
- 108010080367 beta-Arrestins Proteins 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000013262 cAMP assay Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- BTFQKIATRPGRBS-UHFFFAOYSA-N o-tolualdehyde Chemical compound CC1=CC=CC=C1C=O BTFQKIATRPGRBS-UHFFFAOYSA-N 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000000014 opioid analgesic Substances 0.000 description 2
- 229940124636 opioid drug Drugs 0.000 description 2
- 239000004031 partial agonist Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- DTUQWGWMVIHBKE-UHFFFAOYSA-N phenylacetaldehyde Chemical compound O=CCC1=CC=CC=C1 DTUQWGWMVIHBKE-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229960003394 remifentanil Drugs 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000001590 sural nerve Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- ZFSXKSSWYSZPGQ-UHFFFAOYSA-N (2-hydroxycyclopentyl)azanium;chloride Chemical compound Cl.NC1CCCC1O ZFSXKSSWYSZPGQ-UHFFFAOYSA-N 0.000 description 1
- ZHUJMSMQIPIPTF-IBURTVSXSA-N (2r)-2-[[(2s)-2-[[2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ZHUJMSMQIPIPTF-IBURTVSXSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- MNJYZNVROSZZQC-UHFFFAOYSA-N (4-tert-butylphenyl)boronic acid Chemical compound CC(C)(C)C1=CC=C(B(O)O)C=C1 MNJYZNVROSZZQC-UHFFFAOYSA-N 0.000 description 1
- AOTWCYSQDSKAQT-UHFFFAOYSA-N 1,2-dichloro-4-methyl-5-nitrobenzene Chemical compound CC1=CC(Cl)=C(Cl)C=C1[N+]([O-])=O AOTWCYSQDSKAQT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- XPAZYWMYTUESNI-UHFFFAOYSA-N 1-[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylpent Chemical compound C1CCC(C(O)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(C(C)CC)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)CNC(=O)CNC(=O)C(N)CC=1C=CC(O)=CC=1)CC1=CC=CC=C1 XPAZYWMYTUESNI-UHFFFAOYSA-N 0.000 description 1
- YKNUXXRRPRLOBW-UHFFFAOYSA-N 1-azaspiro[3.3]heptane Chemical compound C1CCC21NCC2 YKNUXXRRPRLOBW-UHFFFAOYSA-N 0.000 description 1
- UIOYEIHBWQTVJC-UHFFFAOYSA-N 1-chloro-2,4-difluoro-5-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=C(F)C=C1F UIOYEIHBWQTVJC-UHFFFAOYSA-N 0.000 description 1
- HBGYPLNIBDKWIK-UHFFFAOYSA-N 1-chloro-2,5-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(Cl)C=C1F HBGYPLNIBDKWIK-UHFFFAOYSA-N 0.000 description 1
- BONLKUDAFUJZNP-UHFFFAOYSA-N 1-chloro-4,5-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=C(F)C=C1Cl BONLKUDAFUJZNP-UHFFFAOYSA-N 0.000 description 1
- OORBDHOQLZRIQR-UHFFFAOYSA-N 1-fluoro-4-methyl-2-nitrobenzene Chemical compound CC1=CC=C(F)C([N+]([O-])=O)=C1 OORBDHOQLZRIQR-UHFFFAOYSA-N 0.000 description 1
- PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
- CCDBCHAQIXKJCG-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-one Chemical compound CC(C)N1CCC(=O)CC1 CCDBCHAQIXKJCG-UHFFFAOYSA-N 0.000 description 1
- GISVICWQYMUPJF-UHFFFAOYSA-N 2,4-Dimethylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(C)=C1 GISVICWQYMUPJF-UHFFFAOYSA-N 0.000 description 1
- YSFBEAASFUWWHU-UHFFFAOYSA-N 2,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C(Cl)=C1 YSFBEAASFUWWHU-UHFFFAOYSA-N 0.000 description 1
- RJXOVESYJFXCGI-UHFFFAOYSA-N 2,4-difluoro-1-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1F RJXOVESYJFXCGI-UHFFFAOYSA-N 0.000 description 1
- WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 description 1
- QOJQBWSZHCKOLL-UHFFFAOYSA-N 2,6-dimethylbenzaldehyde Chemical compound CC1=CC=CC(C)=C1C=O QOJQBWSZHCKOLL-UHFFFAOYSA-N 0.000 description 1
- GILLKIJFJOBJCD-UHFFFAOYSA-N 2-(1,1-dioxo-1,4-thiazinan-4-yl)ethanol Chemical compound OCCN1CCS(=O)(=O)CC1 GILLKIJFJOBJCD-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- OSPMNRDGMUPWNO-UHFFFAOYSA-N 2-chloro-4-methylbenzaldehyde Chemical compound CC1=CC=C(C=O)C(Cl)=C1 OSPMNRDGMUPWNO-UHFFFAOYSA-N 0.000 description 1
- JFZJMSDDOOAOIV-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(Cl)N=C1 JFZJMSDDOOAOIV-UHFFFAOYSA-N 0.000 description 1
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 1
- CCHNWURRBFGQCD-UHFFFAOYSA-N 2-chlorocyclohexan-1-one Chemical compound ClC1CCCCC1=O CCHNWURRBFGQCD-UHFFFAOYSA-N 0.000 description 1
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- HPJALMWOZYIZGE-UHFFFAOYSA-N 2-oxa-6-azaspiro[3.3]heptane Chemical compound C1NCC11COC1 HPJALMWOZYIZGE-UHFFFAOYSA-N 0.000 description 1
- ZWUSBSHBFFPRNE-UHFFFAOYSA-N 3,4-dichlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1Cl ZWUSBSHBFFPRNE-UHFFFAOYSA-N 0.000 description 1
- JPHKMYXKNKLNDF-UHFFFAOYSA-N 3,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1F JPHKMYXKNKLNDF-UHFFFAOYSA-N 0.000 description 1
- 125000004917 3-methyl-2-butyl group Chemical group CC(C(C)*)C 0.000 description 1
- XQNVDQZWOBPLQZ-UHFFFAOYSA-N 4-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=C(C=O)C=C1 XQNVDQZWOBPLQZ-UHFFFAOYSA-N 0.000 description 1
- BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical compound FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
- IPQDZFUZVJKAKZ-UHFFFAOYSA-N 4-(trifluoromethyl)cyclohexan-1-one Chemical compound FC(F)(F)C1CCC(=O)CC1 IPQDZFUZVJKAKZ-UHFFFAOYSA-N 0.000 description 1
- DIAWBHLTWNWYGR-UHFFFAOYSA-N 4-chloro-1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC=C1F DIAWBHLTWNWYGR-UHFFFAOYSA-N 0.000 description 1
- UVGYSEIWAOOIJR-UHFFFAOYSA-N 4-chloro-2-fluorobenzaldehyde Chemical compound FC1=CC(Cl)=CC=C1C=O UVGYSEIWAOOIJR-UHFFFAOYSA-N 0.000 description 1
- IVBZHFWJBYTRNG-UHFFFAOYSA-N 4-chloro-2-methoxybenzaldehyde Chemical compound COC1=CC(Cl)=CC=C1C=O IVBZHFWJBYTRNG-UHFFFAOYSA-N 0.000 description 1
- YLXSEAVHGJWSTK-UHFFFAOYSA-N 4-chloro-2-methylbenzaldehyde Chemical compound CC1=CC(Cl)=CC=C1C=O YLXSEAVHGJWSTK-UHFFFAOYSA-N 0.000 description 1
- AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
- OKSDJGWHKXFVME-UHFFFAOYSA-N 4-ethylcyclohexan-1-one Chemical compound CCC1CCC(=O)CC1 OKSDJGWHKXFVME-UHFFFAOYSA-N 0.000 description 1
- ADCFIKGEGWFWEA-UHFFFAOYSA-N 4-fluoro-2-methylbenzaldehyde Chemical compound CC1=CC(F)=CC=C1C=O ADCFIKGEGWFWEA-UHFFFAOYSA-N 0.000 description 1
- UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
- OTXINXDGSUFPNU-UHFFFAOYSA-N 4-tert-butylbenzaldehyde Chemical compound CC(C)(C)C1=CC=C(C=O)C=C1 OTXINXDGSUFPNU-UHFFFAOYSA-N 0.000 description 1
- WCAYVLDBIHEGGQ-UHFFFAOYSA-N 4-tert-butylpiperidin-2-one Chemical compound CC(C)(C)C1CCNC(=O)C1 WCAYVLDBIHEGGQ-UHFFFAOYSA-N 0.000 description 1
- VWYFITBWBRVBSW-UHFFFAOYSA-N 5-chlorothiophene-2-carbaldehyde Chemical compound ClC1=CC=C(C=O)S1 VWYFITBWBRVBSW-UHFFFAOYSA-N 0.000 description 1
- 108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- IQUMIAHZIWJYBU-UHFFFAOYSA-N C1CCNCC1.C1=CC=CC2=NC(=O)N=C21 Chemical class C1CCNCC1.C1=CC=CC2=NC(=O)N=C21 IQUMIAHZIWJYBU-UHFFFAOYSA-N 0.000 description 1
- DQAXEJXYRNDJEC-UHFFFAOYSA-N CC(C)C(CC1)CCC1N(CC1)CCC1N(C(C(CN1CCN2CCOCC2)=C2)=CC(Cl)=C2Cl)C1=O Chemical compound CC(C)C(CC1)CCC1N(CC1)CCC1N(C(C(CN1CCN2CCOCC2)=C2)=CC(Cl)=C2Cl)C1=O DQAXEJXYRNDJEC-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ZEXLJFNSKAHNFH-SYKYGTKKSA-N L-Phenylalaninamide, L-tyrosyl-L-prolyl-L-tryptophyl- Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C1=CC=C(O)C=C1 ZEXLJFNSKAHNFH-SYKYGTKKSA-N 0.000 description 1
- 108010004028 Leucine-2-Alanine Enkephalin Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
- VRKYCNQKLVPQDP-UHFFFAOYSA-N O=C(NCC1=C2)N(C3CCN(CC(C=CC=C4)=C4F)CC3)C1=CC(Cl)=C2Cl Chemical compound O=C(NCC1=C2)N(C3CCN(CC(C=CC=C4)=C4F)CC3)C1=CC(Cl)=C2Cl VRKYCNQKLVPQDP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical group N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 150000005405 azaspiro[5.5]undecanes Chemical class 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 1
- YKFKEYKJGVSEIX-UHFFFAOYSA-N cyclohexanone, 4-(1,1-dimethylethyl)- Chemical compound CC(C)(C)C1CCC(=O)CC1 YKFKEYKJGVSEIX-UHFFFAOYSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DIOQZVSQGTUSAI-NJFSPNSNSA-N decane Chemical compound CCCCCCCCC[14CH3] DIOQZVSQGTUSAI-NJFSPNSNSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Chemical group C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 108010015205 endomorphin 1 Proteins 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 231100000640 hair analysis Toxicity 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- UMJJFEIKYGFCAT-UHFFFAOYSA-N indan-2-one Chemical compound C1=CC=C2CC(=O)CC2=C1 UMJJFEIKYGFCAT-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000004932 little finger Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical group C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- MQWCXKGKQLNYQG-UHFFFAOYSA-N methyl cyclohexan-4-ol Natural products CC1CCC(O)CC1 MQWCXKGKQLNYQG-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000938 nalorphine Drugs 0.000 description 1
- 229960000858 naltrexone hydrochloride Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229940100595 phenylacetaldehyde Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- PQDJYEQOELDLCP-UHFFFAOYSA-N trimethylsilane Chemical compound C[SiH](C)C PQDJYEQOELDLCP-UHFFFAOYSA-N 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Definitions
- the application belongs to the field of medicinal chemistry, and specifically relates to a piperidine derivative and its pharmaceutical composition, preparation method and application.
- opioid analgesics and non-steroidal anti-inflammatory drugs dominate the pain treatment market, and are widely used in surgical analgesia, advanced cancer analgesia and long-term chronic pain, etc. field.
- Opioid analgesics are the main treatment drugs for moderate to severe pain in clinic because of their fast onset of action and strong analgesic effect.
- KOP receptor agonists and DOP receptor agonists although not having the side effects mediated by MOP receptor agonists, each have some side effects of their own.
- KOP receptor agonists can mediate side effects such as dysphoria, sedation, and polyuria, but they have also been found to reduce the rewarding effects of addictive drugs, so they have the potential to be developed as analgesics to overcome opioid dependence.
- DOP receptor After the DOP receptor is activated by the agonist, it will produce a twitching effect, but it also shows that it has a good analgesic effect on chronic pain.
- the DOP receptor will not produce physiological dependence after being activated, abuse dependence less sexual. And also has anxiolytic and antidepressant effects.
- selective KOP receptor or DOP receptor ligand compounds have not been successful in clinical development due to their limited analgesic efficacy.
- NOP receptors The analgesic effect mediated by NOP receptors is more complex than that of other opioid receptor family members.
- the nociceptin/orphanin FQ-NOP receptor system not only inhibits the analgesic effect mediated by opioid receptors, but also reduces Hyperalgesia to mediate analgesic effects.
- NOP receptor agonists have the effect of analgesia and regulating the addiction caused by MOP agonists.
- RO 64-6198 is the first reported small-molecule NOP receptor selective agonist, developed by Roche, and has shown good analgesic effects in non-human primate models and rodent model experiments, and Does not have classic opioid-mediated side effects.
- BU08028 is an analogue of buprenorphine. This molecule has high affinity for four typical opioid receptors. The results of in vitro experiments show that BU08028 is a partial agonist of MOP/NOP receptors. Compared with buprenorphine and remifentanil, BU08028 has higher biological activity on NOP receptors; in non-human primate experiments, compared with buprenorphine and remifentanil, BU08028 showed very high analgesic and anxiolytic activity effect, is less addictive and more importantly does not show significant physiological dependence.
- Nalorphine is a kind of bifunctional opioid drug of MOP receptor antagonist and KOP receptor agonist, which can inhibit the effect of morphine in vivo, and itself can show analgesic activity.
- Bifunctional molecules with high activity on KOP receptors and low or moderate activity on MOP receptors are less addictive than pure MOP receptor agonists, but they have their own dysphoric and carcinogenic effects. Phantom side effects.
- Cebranopadol is a bifunctional agonist of MOP/NOP receptors. Preclinical data show that Cebranopadol also has partial agonistic activity on KOP receptors. Cebranopadol has recently been reported to exhibit reduced tolerability, physiological dependence, and respiratory depression compared to morphine.
- Patent WO2017/096323 discloses AT-121, which is a class of piperidinyl spirocyclic compounds, has high affinity for both MOP receptors and NOP receptors, and is a partial agonist of these two receptors. In the experiment, this molecule showed better analgesic and anti-compulsory effects, and no side effects such as respiratory depression, opioid-induced hypersensitivity and drug dependence.
- the application provides a piperidine derivative and its pharmaceutical composition, preparation method and application.
- This type of compound has novel structure, high affinity and agonistic biological activity of MOP receptor, NOP receptor (ORL-1 receptor) and (or) KOP receptor, and has bifunctional effects on MOP receptor and KOP receptor High selectivity for MOP receptors and NOP receptors (ORL-1 receptors), or high selectivity for bifunctional effects on MOP receptors and NOP receptors (ORL-1 receptors), and some compounds have high G protein bias, so they have unique pharmacological mechanisms.
- the present application provides a compound represented by formula (I), or its stereoisomer, pharmaceutically acceptable salt, solvate, deuterated compound, metabolite or prodrug;
- n 0 or 1
- n 0 or 1
- p 0, 1 or 2;
- R 1 and R 2 are each independently selected from: hydrogen, halogen, C 1-3 alkyl and C 1-3 alkoxyl; and provide; R 1 and R 2 are not hydrogen at the same time;
- R 3 is selected from unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted C 3-8 cycloalkyl, substituted C 3-8 cycloalkyl, unsubstituted Substituted C 4-6 heterocycloalkyl and substituted C 4-6 heterocycloalkyl;
- R is selected from hydrogen, -C 1-3 alkyl - unsubstituted heterocycloalkyl, -C 1-3 alkyl-substituted heterocycloalkyl, -C 1-3 alkyl-substituted spiroheterocycloalkyl , -C 1-3 alkyl-C(O)NR 5 R 6 , -C 1-3 alkyl-NR 7 R 8 , -C 1-4 alkyl unsubstituted-heteroaryl and -C 1- 4 Alkyl-substituted heteroaryl;
- R 5 and R 6 can be hydrogen or C 1-3 alkyl independently, or R 5 and R 6 together form unsubstituted C 4-6 heterocycloalkyl, Or R 5 and R 6 together form a C 4-6 substituted heterocycloalkyl group;
- R 7 and R 8 can be independently hydrogen or C 1-3 alkyl, or R 7 and R 8 together form an unsubstituted C 4
- the present application provides a pharmaceutically acceptable carrier comprising the above-mentioned piperidine derivative or its stereoisomer, pharmaceutically acceptable salt, solvate, deuterated compound, metabolite or prodrug.
- the present application provides the biological activity of the above-mentioned piperidine derivatives or pharmaceutical compositions thereof as MOP receptor and NOP receptor (ORL-1 receptor) agonists.
- the present application provides a method for preparing the above-mentioned piperidine derivatives, the preparation method comprising the following steps:
- X 1 and X 2 represent leaving groups such as bromine respectively, or the compound of formula (I-5) is aldehyde, or ketone, or boronic acid; Pr 1 represents amino protecting group such as tert-butyloxycarbonyl , Benzyloxycarbonyl, etc.
- Figure 1A is the analgesic time-effect curve of compound EX3 of the present application; the experimental results are expressed as mean ⁇ standard error, compared with the blank control group, ### p ⁇ 0.001, compared with the model group, * p ⁇ 0.05, ** * p ⁇ 0.001, differences between groups were compared by one-way analysis of variance Dunnett's, NS, meaningless;
- Figure 1B is the analgesic dose-effect diagram of compound EX3 of the present application; the experimental results are expressed as mean ⁇ standard error, compared with the blank control group, ### p ⁇ 0.001, compared with the model group, * p ⁇ 0.05, *** p ⁇ 0.001, differences between groups were compared by one-way analysis of variance Dunnett's, NS, meaningless;
- Fig. 2 is the result of the application compound EX3 Frey hair and foot weight-bearing experiment; mechanical pain threshold (VonFrey) curve (A) and relative analgesic rate (C) with time; foot weight difference (Weight Bearing) curve with time (B) and relative analgesic rate (D); the experimental results are expressed as mean ⁇ standard error, compared with the control group (G1), * p ⁇ 0.05 means significant difference, &&, $$, ##, ** p ⁇ 0.01 is extremely significant difference.
- the present application provides a compound represented by formula (I), and stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or prodrugs thereof,
- n 0 or 1
- n 0 or 1
- p 0, 1 or 2;
- R 1 and R 2 are each independently selected from: hydrogen, halogen, C 1-3 alkyl and C 1-3 alkoxyl; and provide; R 1 and R 2 are not hydrogen at the same time;
- R 3 is selected from unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted C 3-8 cycloalkyl, substituted C 3-8 cycloalkyl, unsubstituted Substituted C 4-6 heterocycloalkyl and substituted C 4-6 heterocycloalkyl; here, the substituted aryl, substituted heteroaryl, substituted C 3-8 cycloalkyl or substituted C 4-6 heterocycloalkyl is substituted by 1-3 substituents independently selected from the following groups: halogen, C 1-4 alkyl, halogenated C 1-4 alkyl, C 1-4 alkoxy , halogenated C 1-4 alkoxy, aryl and heteroaryl;
- R is selected from hydrogen, -C 1-3 alkyl - unsubstituted heterocycloalkyl, -C 1-3 alkyl-substituted heterocycloalkyl, -C 1-3 alkyl-substituted spiroheterocycloalkyl, -C 1-3 alkyl-C(O)NR 5 R 6 , -C 1-3 alkyl-NR 7 R 8 , -C 1-4 alkyl-unsubstituted heteroaryl and -C 1-4 alkane Base-substituted heteroaryl;
- R 5 and R 6 can be independently hydrogen, or C 1-3 alkyl, or R 5 and R 6 together form C 4-6 unsubstituted heterocycloalkyl, or R 5 and R 6 together form a C 4-6 substituted heterocycloalkyl group
- R 7 and R 8 can be independently hydrogen or C 1-3 alkyl, or R 7 and R 8 together form a C 4-6 substituted heterocycloalky
- n in formula (I) is 0;
- n 0;
- p 0, 1 or 2.
- n 1 in formula (I);
- n 0;
- p 0, 1 or 2.
- n is 0 in formula (I);
- n 1;
- p 0, 1 or 2.
- R 1 and R 2 are each independently selected from: hydrogen, halogen, C 1-3 alkyl; and it is specified that R 1 and R 2 are not hydrogen at the same time.
- R 1 and R 2 are each independently selected from: hydrogen, chlorine, fluorine, C 1-3 alkyl; and it is specified that R 1 and R 2 are not hydrogen at the same time.
- R 1 and R 2 are each independently selected from: hydrogen, chlorine, fluorine, methyl; and it is specified that R 1 and R 2 are not simultaneously hydrogen; alternatively, R 1 and R2 are both chlorine, or R1 is chlorine and R2 is fluorine, or R1 is fluorine and R2 is chlorine, or R1 and R2 are both fluorine, or R1 is fluorine, methane group or chlorine and R2 is hydrogen , or, R1 is hydrogen and R2 is chlorine or fluorine.
- the R in formula (I) is selected from unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl, where the unsubstituted aryl
- the base is phenyl or naphthyl
- the unsubstituted heteroaryl is furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl , pyrazolyl, triazolyl, or tetrazolyl
- the substituted aryl is phenyl or naphthyl substituted by 1-3 independently selected from the following groups: halogen, C 1-4 alkyl , halogenated C 1-4 alkyl, C 1-4 alkoxy, halogenated C 1-4 alkoxy, aryl and heteroaryl
- the substituted heteroaryl is 1-2 independently Fur
- R 3 is phenyl, or phenyl substituted by 1-3 independently selected from the following groups: halogen, C 1-4 alkyl, halogenated C 1-4 Alkyl, C 1-4 alkoxy and halogenated C 1-4 alkoxy; or phenyl substituted by 1-3 independently selected from the following groups: fluorine, chlorine, bromine, iodine, C 1- 4 alkyl, halogenated C 1-4 alkyl, C 1-4 alkoxy and halogenated C 1-4 alkoxy.
- R in formula (I) is phenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 2-chloro-4-fluorophenyl, 2-fluoro-4 -Chlorophenyl, 4-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 2,4-dichlorophenyl, 2,6-dichlorophenyl, 2,4-difluorophenyl , 2-chloro-4-methylphenyl, 2-methyl-4-fluorophenyl, 2-methyl-4-chlorophenyl, 2-methoxy-4-chlorophenyl, 2,4- Dimethylphenyl, 2,6-dimethylphenyl, 2,4,6-trimethylphenyl, 4-tert-butylphenyl, 2-chlorophenyl, 2-methylphenyl, 2 -fluorophenyl, 2-methoxyphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-flu
- R in formula (I) is furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl , triazolyl, or tetrazolyl, optionally, substituted by 1-2 groups independently selected from the following groups: fluorine, chlorine, bromine, iodine, C 1-4 alkyl, halogenated C 1-4 Alkyl, C 1-4 alkoxy and halogenated C 1-4 alkoxy; preferably, R 3 is 5-trifluoromethylpyridin-2-yl, or 5-chlorothiophen-2-yl.
- R 3 is unsubstituted C 3-8 cycloalkyl or substituted C 3-8 cycloalkyl, here, the unsubstituted C 3-8 cycloalkyl , the C 3-8 cycloalkyl in the substituted C 3-8 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; the substituted C 3 -8 Cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl substituted by 1-3 independently selected from the following groups: fluorine, chlorine, bromine, iodine , C 1-4 alkyl, halogenated C 1-4 alkyl, C 1-4 alkoxy, halogenated C 1-4 alkoxy and
- R in formula (I) is cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, 4-tert-butylcyclohexyl, 4-isopropylcyclohexyl, 4-ethylcyclohexyl, 4-methylcyclohexyl, 4-trifluoromethylcyclohexyl, 2,3-dihydro-1H-inden-2-yl, or 2-chlorocyclohexyl.
- R 3 is unsubstituted C 4-6 heterocycloalkyl or substituted C 4-6 heterocycloalkyl, where the unsubstituted C 4-6 heterocyclo
- the C 4-6 heterocycloalkyl in the alkyl or substituted C 4-6 heterocycloalkyl is tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, or piperazinyl;
- the substituted C 4-6 heterocycloalkyl is tetrahydrofuranyl, tetrahydropyrrolyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, or piperazine substituted by 1-3 independently selected from the following groups Base: fluorine, chlorine, bromine, iodine, C 1-4 alkyl, halogenated C 1-4 alkyl, C 1-4 alkoxy, halogenated C
- R 4 is selected from: hydrogen, -C 1-3 alkyl-unsubstituted heterocycloalkyl selected from at least one of oxa and thia, -C 1 -3 alkyl-substituted heterocycloalkyl selected from at least one of oxa and thia, -C 1-3 alkyl-substituted spiroheterocycloalkyl, -C 1-3 alkyl-C( O) NR 5 R 6 ,-C 1-3 alkyl-NR 7 R 8 ,-C 1-4 alkyl-unsubstituted heteroaryl group selected from at least one of aza, oxa and thia , and -C 1-4 alkyl-substituted heteroaryl group selected from at least one of aza, oxa and thia; here, R 5 and R 6 can be independently hydrogen, or C 1-3 Alkyl, or R 5 and R 6 and their connecting N
- R 4 is selected from hydrogen, m is 0 and n is 1.
- R in formula (I) is selected from: -C 1-3 alkyl-unsubstituted C 2-6 heterocycloalkyl selected from at least one of oxa and thia, - C 1-3 alkyl-substituted C 2-6 heterocycloalkyl selected from at least one of oxa and thia, -C 1-3 alkyl-substituted spiroheterocycloalkyl, -C 1- 3 alkyl-C (O) NR 5 R 6 , -C 1-3 alkyl-NR 7 R 8 , -C 1-4 alkyl-unsubstituted and selected from aza, oxa and thia at least A C 3-6 heteroaryl, and -C 1-4 alkyl-substituted and selected from at least one of aza, oxa and thia C 3-6 heteroaryl; here, R 5 and R 6 can be independently hydrogen, or C 1-3 alkyl, or R
- R in formula (I) is hydrogen, 2-(morpholinyl)ethyl, 2-(1,1-dioxothiomorpholinium)ethyl, 2-(4-methyl Basepiperazin-1-yl)ethyl, 2-(4-acetylpiperazin-1-yl)ethyl, 2-(3-oxopiperazin-1-yl)ethyl, 2-(pyrrolidine -1-yl)ethyl, 2-(piperidin-1-yl)ethyl, 2-(N,N'-dimethylamino)ethyl, 2-(2-oxopyrrolidin-1-yl) Ethyl, N, N'-dimethylacetamido, oxapropane-2-ylmethyl, or 2-(2-oxa-6-azaspiro[3.3]heptane-6-yl)ethyl and when R4 is hydrogen, m is 0 and n is 1 .
- R 4 is -C 1-3 alkyl-substituted spiroheterocycloalkyl, and the substituted spiroheterocycloalkyl can be 0 or 1 oxa azaspiro [3.3] Heptane, azaspiro[3.5]nonane, azaspiro[3.4]octane, azaspiro[5.5]undecane, or azaspiro[4.5]decane.
- the compound of the formula (I) is the compound shown below, and its stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or prodrugs:
- the present application also discloses a pharmaceutical composition, which includes: effective doses of the piperidine derivatives represented by the general formula (I) described in the present application and stereoisomers thereof, pharmaceutical Pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or prodrugs, or further include one or more other therapeutic agents and pharmaceutically acceptable carriers or excipients.
- the pharmaceutically acceptable excipient(s) may, for example, be selected from carriers (e.g. solid, liquid or semi-solid carriers), adjuvants, diluents (e.g. solid diluents such as fillers or fillers; and liquid diluents such as solvents and co-solvents), granulating agents, binders, glidants, coatings, release-controlling agents (e.g.
- binders disintegrants, buffers, lubricants preservatives, antifungal and antibacterial agents, antioxidants, buffers, tonicity regulators, thickeners, flavor enhancers, sweeteners, pigments, plasticizers, taste-masking agents, stabilizers or pharmaceutical combinations any other excipients routinely used in pharmaceuticals.
- pharmaceutically acceptable refers to those compounds, materials, compositions and/or dosage forms, where they are suitable within the scope of sound medical judgment for contacting the tissues of a subject (e.g., a human subject) without There is no undue toxicity, irritation, allergic reaction or other problems or complications commensurate with a reasonable benefit/risk ratio. Each excipient must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.
- compositions containing compounds of formula (I) may be formulated according to known techniques, see for example, Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA, USA.
- the pharmaceutical composition may be in any form suitable for oral, parenteral, topical, intranasal, intrabronchial, sublingual, ophthalmic, otic, rectal, intravaginal or transdermal administration.
- Pharmaceutical dosage forms suitable for oral administration include tablets (coated or uncoated), capsules (hard or soft shell), caplets, pills, lozenges, syrups, solutions, powders, Granules, elixirs and suspensions, sublingual tablets or patches such as buccal patches.
- the pharmaceutical composition further includes one or more additional therapeutic agents.
- the present application provides piperidine derivatives represented by the general formula (I) described in the present application and their stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or Prodrugs, for pharmaceutical use.
- the present application provides the piperidine derivatives represented by the general formula (I) described in the present application and their stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, Metabolites or prodrugs for modulating ⁇ opioid receptors (MOPR) and kappa opioid receptors (KOPR) or ⁇ opioid receptors (MOPR) and nociceptin/orphanin receptors (NOPR or ORL- 1 receptor).
- MOPR ⁇ opioid receptors
- KPR kappa opioid receptors
- MOPR ⁇ opioid receptors
- NOPR nociceptin/orphanin receptors
- the present application provides the piperidine derivatives represented by the general formula (I) described in the present application and their stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, Metabolites or prodrugs for the treatment of pain, anxiety, depression, alcohol addiction, substance abuse/dependence.
- the present application also provides piperidine derivatives represented by general formula (I) or their stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or prodrugs or
- the compositions of the present application are useful in methods of treating pain, anxiety, depression, alcohol addiction, substance abuse/dependence.
- the pain may be selected from: acute pain, chronic pain, bone pain, arthralgia, postoperative pain, muscle pain, dental pain, headache, inflammatory pain, neuropathic pain, and Crohn's disease-associated abdominal pain.
- the present application provides the piperidine derivatives represented by the general formula (I) described in the present application or their stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, Use of metabolites or prodrugs, or pharmaceutical compositions thereof, in the preparation of medicines for treating pain, anxiety, depression, alcohol addiction, and substance abuse/dependence.
- the application provides the above use, the pain may be selected from: acute pain, chronic pain, bone pain, arthralgia, postoperative pain, muscle pain, toothache, headache, inflammatory pain, neuropathic pain Abdominal pain associated with Crohn's disease.
- the present application provides a mu opioid receptor (MOPR) and kappa opioid receptor (KOPR) co-mediated or mu opioid receptor (MOPR) and nociceptin for treating patients / Orphanin receptor (NOPR or ORL-1 receptor) co-mediated disorder method, said method comprising administering the piperidine derivatives represented by general formula (I) or Stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or prodrugs thereof, or pharmaceutical compositions thereof.
- MOPR mu opioid receptor
- KPR kappa opioid receptor
- NOPR Orphanin receptor
- ORL-1 receptor Orphanin receptor
- the application provides a method for treating or preventing pain, anxiety, depression, alcohol addiction, substance abuse/dependence in a patient, the method comprising administering the present application to a patient in need thereof.
- the pain may be selected from the group consisting of: acute pain, chronic pain, bone pain, arthralgia, postoperative pain, muscle pain, dental pain, headache, inflammatory pain, neuropathic pain, and Crohn's disease-related abdominal pain.
- the present application provides a method for modulating mu opioid receptor (MOPR) and kappa opioid receptor (KOPR) or mu opioid receptor (MOPR) and nociceptin/orphanin receptor (NOPR or ORL-1 receptor), the method comprises administering the piperidine derivatives represented by the general formula (I) described in the present application or its stereoisomers, pharmaceutically acceptable salts, solvents compounds, deuterated compounds, metabolites or prodrugs, or the pharmaceutical composition.
- MOPR mu opioid receptor
- KPR kappa opioid receptor
- MOPR mu opioid receptor
- NOPR nociceptin/orphanin receptor
- ORL-1 receptor nociceptin/orphanin receptor
- the present application provides a method for modulating mu opioid receptor (MOPR) and kappa opioid receptor (KOPR) or mu opioid receptor (MOPR) and nociceptin/orphanin receptor body (NOPR or ORL-1 receptor), thereby treating or preventing pain, anxiety, depression, alcohol addiction, substance abuse/dependence in a patient, the method comprising administering the present application to a patient in need thereof Piperidine derivatives represented by general formula (I) or their stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or prodrugs, or the pharmaceutical composition.
- the pain may be selected from the group consisting of: acute pain, chronic pain, bone pain, arthralgia, postoperative pain, muscle pain, dental pain, headache, inflammatory pain, neuropathic pain, and Crohn's disease-related abdominal pain.
- the present application provides a method for preparing the above-mentioned piperidine derivatives or their stereoisomers, pharmaceutically acceptable salts, solvates, deuterated compounds, metabolites or prodrugs, the preparation
- the method includes the following steps:
- X 1 and X 2 represent respectively leaving group such as bromine, chlorine, or sulfonate group etc., or formula (I-5)
- the compound is an aldehyde, or a ketone, or a boronic acid
- Pr 1 represents an amino protecting group such as tert-butyloxycarbonyl, benzyloxycarbonyl CBz or fluorenylmethyloxycarbonyl Fmoc, etc.;
- the definitions of other groups in formulas (I-1) to (I-7) and formula (I) are as above.
- the compound of the application has good opioid receptor agonistic activity, is suitable for medicine and has clinical application value. Moreover, the compounds of the present application have simple synthesis steps, so they have good economic value.
- the carbon, hydrogen, oxygen, sulfur, nitrogen or halogens involved in the groups and compounds described in the application include their isotopes, and the carbon, hydrogen, oxygen, sulfur, sulfur, hydrogen, oxygen, sulfur, Nitrogen or halogen is optionally further replaced by one or more of their corresponding isotopes, wherein isotopes of carbon include 12 C, 13 C, and 14 C, and isotopes of hydrogen include protium (H), deuterium (D, also known as heavy hydrogen ), tritium (T, also known as tritium), the isotopes of oxygen include 16 O, 17 O and 18 O, the isotopes of sulfur include 32 S, 33 S, 34 S and 36 S, and the isotopes of nitrogen include 14 N and 15 N, the isotope of fluorine is 19 F, the isotope of chlorine includes 35 Cl and 37 Cl, and the isotope of bromine includes 79 Br and 81 Br.
- isotopes of carbon include 12 C, 13 C, and
- Alkyl refers to a linear and branched monovalent saturated hydrocarbon group, the main chain includes 1 to 10 carbon atoms, examples of alkyl include but are not limited to methyl, ethyl, n-propyl, isopropyl, n- Butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, n-hexyl Base, n-heptyl, n-octyl, n-nonyl and n-decyl, etc.; said alkyl group can be further substituted by any substituent.
- Cycloalkyl means a monovalent saturated carbocyclic hydrocarbon group, monocyclic, usually having 3 to 10 carbon atoms, non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl Base etc. Said cycloalkyl group may be optionally further substituted by any substituent.
- Heterocycloalkane refers to a saturated cyclic hydrocarbon group containing at least one heteroatom, a single ring, and the heteroatoms are N, O, S, P and their oxidized forms. Non-limiting examples include aziridinyl, oxygen Heterocyclopropyl, thiiridine, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, pyrazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, etc.
- the heterocycloalkane may optionally be further substituted by any substituent.
- Aryl means a 6 to 14 membered all-carbon monocyclic or fused polycyclic (that is, rings sharing adjacent pairs of carbon atoms) group, preferably 6 to 10 membered, having a conjugated pi-electron system, such as phenyl and naphthyl.
- the aryl ring includes an aryl ring as described above fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring bonded to the parent structure is an aryl ring.
- Aryl groups may be substituted or unsubstituted, and when substituted, substituents may be substituted at any available point of attachment, preferably independently and optionally selected from hydrogen atoms, halogen, alkyl, alkane One or more substituents in oxy, haloalkyl, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
- Heteroaryl refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 5 to 10 membered (eg 5, 6, 7, 8, 9 or 10 membered), more preferably 5 or 6 membered, eg furyl, thienyl, pyridyl, pyrrolyl, N-alkyl Pyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, etc.
- the heteroaryl ring includes a heteroaryl as described above fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring
- “Pharmaceutically acceptable salt” refers to a compound that maintains the biological effectiveness and properties of the free acid or free base, and the free acid is mixed with a non-toxic inorganic base or organic base, or the free acid is mixed with a non-toxic Those salts obtained by reaction with toxic inorganic or organic acids.
- Carrier refers to a carrier or diluent that does not cause significant irritation to the organism and does not abrogate the biological activity and properties of the administered compound.
- Excipient refers to an inert substance added to a pharmaceutical composition to further depend on the administration of the compound.
- excipients include, but are not limited to, calcium carbonate, calcium phosphate, various sugars and different types of starch, cellulose derivatives (including microcrystalline cellulose), gelatin, vegetable oils, polyethylene glycols, diluents, synthetic Granules, lubricants, binders, disintegrants, etc.
- Prodrug refers to a compound that can be converted under physiological conditions or by solvolysis into a biologically active compound of the present application.
- the prodrugs of the present application are prepared by modifying the phenolic group in the compound, which modification can be removed routinely or in vivo to give the parent compound.
- the prodrugs of the present application are administered to a mammalian individual, the prodrugs are cleaved to form free hydroxyl groups, respectively.
- Examples of prodrugs include, but are not limited to, phenolic hydroxyl and phosphate to sodium salt derivatives of compounds of the present application.
- Effective dose means the amount of a compound that causes a physiological or medical translation of a tissue, system, or subject that is sought, including one or more doses sufficient to prevent the disease or condition being treated when administered in a subject. The amount of compound that causes or alleviates a symptom to some extent.
- Solvate refers to a compound of the present application or a salt thereof, which also includes stoichiometric or non-stoichiometric solvents bound by intermolecular non-covalent forces.
- solvent When the solvent is water, it is a hydrate.
- Alkyl optionally substituted by F means that the alkyl group may but not necessarily be substituted by F, and the description includes the case where the alkyl group is substituted by F and the case where the alkyl group is not substituted by F.
- High-performance liquid chromatography was determined by an Agilent Technologies 1260 Infinity liquid chromatograph, and a YMC Triart C18 EXRS (4.6*150mm, 3 ⁇ m) chromatographic column was used for detection. Gradient elution conditions: at a flow rate of 1.0mL/min, 30-10% solvent A1 and 70-90% solvent B1, then 90% B1 and 10% A1 for 0.5min, the percentage is the volume percentage of a certain solvent in the total solvent volume . Wherein solvent A1: 0.1% aqueous ammonia solution; solvent B1: acetonitrile. The percentage is the volume percentage of the solute in the solution; injection volume: determined by the concentration of the reaction solution, generally 0.2mg/mL concentration sample, injection 2 ⁇ L; detection wavelength: 254/220nm; chromatographic column temperature: 30°C.
- reaction system was cooled to room temperature, and the reaction solution was slowly poured into an ice-water mixture (500 mL) under stirring conditions, a large amount of yellow solids were precipitated, filtered, and the filter cake was washed with a small amount of water and dried to obtain Yellow solid product 17.58g, yield 94.59%.
- the reaction was stirred at room temperature for 24 hours. It was detected by the TLC plate that the basic reaction of the raw materials was basically complete, and the reaction was quenched by adding saturated aqueous sodium bicarbonate solution to the reaction bottle, and extracted three times with dichloromethane, combined the organic phases, washed with saturated brine, dried over anhydrous sodium sulfate, and filtered , the solvent was evaporated under reduced pressure by a rotary evaporator to obtain a crude product, which was separated and purified by silica gel chromatography (the mobile phase was dichloromethane and methanol, the ratio was 150:1 ⁇ 70:1) to obtain 55 mg of a white solid product, the yield 50.6%.
- the reaction was quenched by adding saturated NaHCO 3 aqueous solution, the layers were separated, the organic phase was washed with saturated NaCl aqueous solution, dried with anhydrous MgSO 4 , filtered, and spin-dried to obtain a light brown oily crude product 39b (2.15 g, yield 74.88%).
- the crude product was directly used in the next reaction without further purification.
- the reaction system was cooled to room temperature, and under stirring, ice water was added dropwise to the reaction system to quench the reaction, extracted with ethyl acetate (150mL ⁇ 3), and the organic phase was washed with saturated NH4Cl aqueous solution and saturated NaCl aqueous solution, respectively. After drying with anhydrous Na 2 SO 4 , filter, and evaporate the solvent with a rotary evaporator to obtain a light brown solid crude product, which is dispersed in a mixed solvent of petroleum ether/ethyl acetate (1% ethyl acetate), and stirred for 30 Minutes later, the product was filtered as a white solid (2.91 g, yield 83.5%).
- Compound EX40 was synthesized by using 40c and 2-chloro-4-fluorobenzyl bromide as raw materials, and synthesized according to the synthesis method of Example 39 to obtain a white solid product (198 mg, yield 69.05%).
- the reaction mixture was cooled to room temperature, filtered through diatomaceous earth, and the filter cake was washed with absolute ethanol, the filtrate was collected, and the solution was evaporated under reduced pressure using a rotary evaporator to obtain a white solid, which was dissolved in ethyl acetate Ester (100 mL), and a small amount of water (25 mL) was added, a large amount of white solid precipitated out, filtered and dried to obtain 2.00 g of white solid product, yield 86.41%. used directly in the next reaction.
- Example 48A 5,6-Dichloro-1-(2-(dimethylamino)ethyl)-3-(1-(trans-4-isopropylcyclohexyl)piperidin-4-yl) -Synthesis of 1,3-dihydro-2H-benzo[d]imidazol-2-one (compound EX48A)
- the reaction mixture was cooled to room temperature, filtered through diatomaceous earth, and the filter cake was washed with absolute ethanol, the filtrate was collected, and the solution was evaporated under reduced pressure using a rotary evaporator to obtain a yellow solid, which was dissolved in ethyl acetate ester (100mL), and add a small amount of water (25mL), filter out insoluble matter, separate the liquid, collect the organic phase, add anhydrous Na 2 SO 4 to dry, filter, use a rotary evaporator to remove the solvent under reduced pressure to obtain a crude product, Separation and purification by silica gel column chromatography (mobile phase: petroleum ether and ethyl acetate, ratio gradient 10:1-3:1) gave a light yellow solid product (1.86 g, yield 81.4%).
- the crude product (590mg, 1.58mmol) was dissolved in dry tetrahydrofuran (15mL), and argon protection was replaced, and N, N'-carbonyldiimidazole (358mg, 2.21mmol) was added dropwise to the reaction system in dichloromethane ( 6mL) solution, stirred and reacted at room temperature for 18 hours, and the reaction was basically complete as monitored by a TLC plate.
- reaction mixture was evaporated to remove the solvent by a rotary evaporator under reduced pressure to obtain a crude product, which was separated and purified by basic alumina column chromatography (the mobile phase was petroleum ether and ethyl acetate, and the ratio gradient was 5:1-1:1 ) to give the product as a white solid (158 mg, yield 78.9%).
- 53b was synthesized according to the synthesis method of 39c to obtain 231 mg of a white solid product with a yield of 35.88%.
- 1 H NMR 400MHz, chloroform-d
- Example 69B 1-(1-((1S,4S)-4-isopropylcyclohexyl)piperidin-4-yl)-5-methyl-3-(2-morpholinoethyl)-1, 3-Dihydro-2H-benzo[d]imidazol-2-one
- Example 70B 5-Chloro-1-(1-((1S,4S)-4-isopropylcyclohexyl)piperidin-4-yl)-3-(2-morpholinoethyl)-1,3 -Dihydro-2H-benzo[d]imidazol-2-one
- Example 71B 5-fluoro-3-(1-((1S,4S)-4-isopropylcyclohexyl)piperidin-4-yl)-1-(2-morpholinoethyl)-1,3 -Dihydro-2H-benzo[d]imidazol-2-one
- the working solution was 50mM Tris pH 7.4, 5mM MgCl 2
- the washing buffer was 50mM Tris pH 7.4, stored at 4°C
- 0.5% BSA solution 0.5mL BSA was added to 100mL double-distilled water, stored at 4°C).
- the reaction system was 500 ⁇ L, and 100 ⁇ L of working solution and 5 ⁇ L of compound solution (1% DMSO, 99% water) were added to a 96-well deep-well plate, and shaken (5 min, 500 rpm).
- compound solution 1% DMSO, 99% water
- Max and Min complex numbers are in the same unit as Y;
- the binding affinity, L is the concentration of [ 3 H]-radioligand used.
- This application is represented by EX3, EX6, EX16, EX17, EX54, EX58 and EX67, etc.
- the compound shows high selectivity and high affinity for MOP receptor and KOP receptor, which can be A bifunctional agonist acting on the MOP receptor KOP receptor, according to the existing literature reports, may It can reduce the side effects such as addiction of single-selective MOP receptor agonists, and at the same time, through the MOP receptor
- the euphoric effect produced by the agonist of KOP may balance the dysphoria, Disgust and other side effects, so that it is possible to achieve the purpose of good analgesic effect and small side effects; with EX12B Compounds represented by EX48B and EX48B showed high selectivity and high Affinity, this MOPr/NOPr dual-function agonist can enhance the gene expression by stimulating the NOP receptor Activating the analgesic effect of MOP receptors and inhibiting the release of dopamine reduces addiction, and it is possible to develop New non
- Opioid receptors are G protein-coupled receptors, mainly coupled with G i protein. When it is activated by ligand binding, it can inhibit the activity of adenylyl cyclase through the G i protein, thereby reducing the level of intracellular cAMP.
- the cAMP kit (LANCE Ultra cAMP kit, PE) was used to detect the agonistic or inhibitory effects of the compounds on four opioid receptors (MOPr, KOPr, DOPr, NOPr (ORL-1)).
- the cAMP assay is a competitive immunoassay used to detect the accumulation of intracellular cAMP, and the measured signal value is inversely correlated with the concentration of cAMP.
- Cell lines stably expressing opioid receptors (CHO-hMOPr, CHO-hNOPr, HEK293-hKOPr, HEK293-hDOPr), digested cells, centrifuged, resuspended with assay buffer containing 0.5mM IBMX, counted, 5 ⁇ l per well A density of approximately 3000 cells was seeded into 384-well cell culture plates. Dilute the compound with experimental buffer to make a 4 ⁇ solution, add 2.5 ⁇ l of the 4 ⁇ compound to each well, and incubate at 37° C. for 10 minutes. Then add 2.5 ⁇ l 4 ⁇ Forskolin and incubate at 37°C for 30min.
- Endomorphin 1 was selected as the MOPr positive compound
- Nociceptin was selected as the NOPr (ORL-1) positive compound
- Dynorphin A 1-10 was selected as the KOPr positive compound
- DADLE was selected as the DOPr positive compound.
- the test compound detection concentration starts from 10 ⁇ M, 3-fold dilution, 10 concentrations, double-well detection.
- Ratio (665/620) was plotted against the concentration of the compound, and GraphPad Prism 8.0 (GraphPad Software, San Diego, California USA) software was used for nonlinear regression method for curve fitting and EC 50 calculation.
- the preferred compound cAMP agonistic function test results show that for MOP receptors and KOP receptors Compounds with dual selectivity for both MOP receptors and KOP receptors also showed good stimulation. Animal biological activity, bifunctional agonist of MOP receptor/KOP receptor. Similarly, for MOP receptors Compounds that are dual-selective for NOP receptors also have good agonism for both opioid receptors biological activity.
- Formalin-induced inflammatory pain pharmacodynamic animal model was established by Dubuisson and Dennis in 1977. Through long-term verification of experiments, formalin diluted by a certain multiple was injected subcutaneously into the rear paw of rats with a micro-injector. A persistent noxious stimulus can be produced, causing animals to respond spontaneously to pain behaviors.
- mice SPF grade male SD rats, 6-7 weeks old, with a body weight ranging from 160 to 180 g; under the premise of meeting the research purpose and scientific standards, use as few animals as possible.
- mice were adaptively raised in the animal breeding room for one week to make them adapt to the environment.
- the room temperature was kept at 22 ⁇ 2°C, and the light was illuminated to avoid strong sound and light stimulation.
- the rats were randomly divided into 6-8 groups, and the rats were numbered. All test experiments were carried out between 8:00 am and 12:00 am.
- the grouped rats were placed in the experimental test box (transparent and visible) for 60 minutes a day for a total of 3 days .
- test compound solution The solvent system is 5% DMSO + 10% Solutol + 85% normal saline, according to the requirements of the test experiment, it is now made into the actual required concentration;
- the method of administration in this experiment was subcutaneous injection.
- the animal experiment environment was kept until the 6th day to carry out the experiment, and the rat body weight, room temperature, humidity, and routine control parameters were recorded.
- the rats were dosed according to body weight, and 50 ⁇ l of 2% formalin solution was subcutaneously injected into the dorsum of the rats 15 minutes after the administration to establish a model.
- %MPE (1-the number of times of exercise of the administration group/the number of times of exercise of the negative control group) ⁇ 100%
- the measurement data are represented by mean ⁇ standard error. All data statistics are carried out by SPSS13.0 statistical software. Data with differences (p ⁇ 0.05) were subjected to LSD multiple comparison analysis, and p ⁇ 0.05 was considered statistically different; data with uneven variance (p ⁇ 0.05) were subjected to Kruskal-wallis non-parametric test, and those with differences (p ⁇ 0.05) The data were compared by Mann-Whitney pairwise analysis, and p ⁇ 0.05 was considered statistically significant. GraphPad Prism 8.0 (GraphPad Software, San Diego, California USA) software was used for drawing.
- the time-response curve basically coincides with the effect curve of the morphine group (mor) within the time interval of 0 to 40 minutes, and then the time-response curve gradually approaches Model group (model), which indicates that the compound EX3 (10mg/kg) has a good analgesic effect in the time interval of 0-40min, which is equivalent to the analgesic effect of morphine 3mg/kg.
- the Spared Nerve Injury (SNI) animal model was developed to study the pharmacological mechanism of neuropathic pain.
- the model was established by means of manual surgery, which can produce persistent and regenerative pain hypersensitivity on the operative side, simulating the typical symptoms of clinical neuropathic pain disorders.
- the rats in the operation group ligated the tibial nerve and the common peroneal nerve with silk thread, cut off the tibial nerve and the common peroneal nerve respectively, and ensured the integrity of the sural nerve, and sutured the muscles and epidermis layer by layer. After the operation, 60,000 units of penicillin were injected subcutaneously into each rat. They were placed in cages and raised, and the drug administration experiment was carried out on the 10th day after the operation.
- the mean value was taken as the balance value of the weight difference between the two hind limbs of the animal.
- the time points of mechanical pain threshold and foot weight-bearing test were before modeling, before administration and 1, 2 and 4 hours after administration, a total of 5 detection points.
- the rats were randomly divided into 5 groups (8 rats in each group), which were vehicle control group (5%DMSO+10% Solutol HS15+85% normal saline), positive control group (gabapentin, 100mg/kg, dosage is converted according to gabapentin clinical dosage), test compound high, medium and low dose groups (10, 3 and 1mg/kg), positive control group adopts the The same way of oral administration, the other experimental groups were administered by subcutaneous injection in the abdomen, and all experimental groups were administered in a single dose.
- the results of the 1h Fry hair test after administration show that three doses of compound EX3 can improve the mechanical pain threshold of animals to a certain extent, especially the middle and high doses The most obvious, compared with the model group, there was a very significant difference (p ⁇ 0.01).
- the measured mechanical pain thresholds of the rats in the middle and high dose groups were 7.0 ⁇ 0.1g and 9.5 ⁇ 0.2g, respectively, and the average relative analgesic rates of the Fry hair were respectively 12.93% and 49.02%, the analgesic effect of the high-dose group was better than that of the positive control group (gabapentin, 100mg/kg, the average relative analgesic value of Fraimau was 29.71%).
- the load-bearing weight of the two hind feet of the SNI model rat is unbalanced.
- this experiment measures the weight-bearing difference between the two hind feet of the animal (left foot-right foot ), take the mean value as the balance value of the weight difference between the two hind feet of the animal.
- the test time points are the same as the Frymao test.
- the balance value of the foot weight difference of the model group animals increased significantly after modeling, which was 59.87 ⁇ 1.60g (3.88 ⁇ 0.56g before the operation).
- the relative analgesic rate of the low-dose compound EX3 group with foot weight is still maintained.
- the balance value of the rear foot weight difference in the high-dose group (10mg/kg) rats was 46.54 ⁇ 0.80g, and the average relative analgesic rate of foot weight was 20.03%, which was still maintained at a relatively high level, slightly better than the positive In the control group (the relative analgesic rate mean value of foot weight is 17.55%)
- the rear foot weight difference balance value of the compound EX3 high-dose group rats still has a very significant difference compared with the model group (p ⁇ 0.01),
- the average relative analgesic rate of foot weight bearing was 15.38%, which was slightly better than that of the positive control group (the average relative analgesic rate of foot weight bearing was 14.07%).
- the compound EX3 can effectively inhibit the neuralgia in rats, and it has a good dose dependence.
- the analgesic effect is consistent with the drug metabolism cycle, and the drug exerts its maximum effect at 1 hour
- the high-dose group (10mg/kg) has a certain analgesic advantage, and the action time is longer, and it still has a good analgesic effect at the 4th hour.
- the analgesic effect superior to that of the positive control gabapentin was exhibited at a low dose.
- the compounds disclosed in this application preferably some of them, have been evaluated for in vivo pharmacodynamics using the above method, and the results show that the compounds disclosed in this application have good efficacy in treating inflammatory pain and neuropathic pain. Through continuous observation of the phenomena and data analysis during the experiment, the compound disclosed in the present application has less side effects such as constipation and itching than the positive control.
Abstract
Description
Claims (24)
- 一种如式(I)所示的化合物,其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,n是0或1;m是0或1;p是0、1或2;R 1和R 2各自独立地选自:氢、卤素、C 1-3的烷基和C 1-3的烷氧基;并规定R 1和R 2不同时为氢;R 3选自未取代的芳基、取代的芳基、未取代的杂芳基、取代的杂芳基、未取代的C 3-8环烷基、取代的C 3-8环烷基、未取代的C 4-6杂环烷基和取代的C 4-6杂环烷基;这里,所述取代的芳基、取代的杂芳基、取代的C 3-8环烷基或取代的C 4-6杂环烷基被1-3个独立地选自下列基团的取代基所取代:卤素、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基、卤代C 1-4烷氧基、芳基和杂芳基;R 4选自氢、-C 1-3烷基-未取代杂环烷基、-C 1-3烷基-取代杂环烷基、-C 1-3烷基-取代螺杂环烷基、-C 1-3烷基-C(O)NR 5R 6、-C 1-3烷基-NR 7R 8、-C 1-4烷基-未取代杂芳基和-C 1-4烷基-取代杂芳基;这里,R 5和R 6可独立地为氢、或C 1-3烷基,或R 5和R 6共同组成C 4-6的未取代的杂环烷基,或R 5和R 6共同组成C 4-6的取代杂环烷基;R 7和R 8可独立地为氢、或C 1-3烷基,或R 7和R 8共同组成C 4-6的未取代的杂环烷基,或R 7和R 8共同组成C 4-6的取代杂环烷基; 并规定R 4为氢时,m为0而n为1。
- 如权利要求1所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,n为0;m为0;p是0、1或2。
- 如权利要求1所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,n为1;m为0;p是0、1或2。
- 如权利要求1所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,n为0;m为1;p是0、1或2。
- 如权利要求1所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,R 1和R 2各独立地选自:氢、卤素、C 1-3的烷基;并规定,R 1和R 2不同时为氢。
- 如权利要求5所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,R 1和R 2各独立地选自:氢、氯、氟、C 1-3的烷基;并规定,R 1和R 2不同时为氢。
- 如权利要求6所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,R 1和R 2各独立地选自:氢、氯、氟、甲基;并规定,R 1和R 2不同时为氢;可选地,R 1和R 2都是氯, 或者,R 1为氯而R 2为氟,或者,R 1为氟而R 2为氯,或者,R 1和R 2都是氟,或者,R 1为氟、甲基或氯而R 2为氢,或者,R 1为氢而R 2为氯或氟。
- 如权利要求1所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,所述R 3选自未取代的芳基、取代的芳基、未取代的杂芳基和取代的杂芳基,这里,所述的未取代的芳基为苯基或萘基;所述为未取代的杂芳基为呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、哒嗪基、咪唑基、吡唑基、三唑基、或四唑基;所述取代的芳基为被1-3个独立地选自下列基团所取代的苯基或萘基:卤素、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基、卤代C 1-4烷氧基、芳基和杂芳基;所述取代的杂芳基为被1-2个独立地选自下列基团所取代的呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、哒嗪基、咪唑基、吡唑基、三唑基、或四唑基:卤素、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基、卤代C 1-4烷氧基、芳基和杂芳基。
- 如权利要求8所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,所述R 3为苯基,或者被1-3个独立地选自下列基团取代的苯基:卤素、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基和卤代C 1-4烷氧基;或者被1-3个独立地选自下列基团取代的苯基:氟、氯、溴、碘、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基和卤代C 1-4烷氧基。
- 如权利要求9所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,所述R 3为苯基、3,4-二氯苯基、3,4-二氟苯基、2-氯-4-氟苯基、2-氟-4-氯苯基、4-三氟甲基苯基、4-三氟甲氧基苯基、2,4-二氯苯基、2,6-二氯苯基、2,4-二氟苯基、2-氯-4-甲基苯基、2-甲基-4-氟苯基、2-甲基-4-氯苯基、2-甲氧基-4-氯苯基、2,4-二甲基苯基、2,6-二甲基苯基、2,4,6-三甲基苯基、4-叔丁基苯基、2-氯苯基、2-甲基苯基、2-氟苯基、2-甲氧基苯基、4-氯苯基、4-氟苯基或4-甲氧基苯基。
- 如权利要求8所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,所述R 3为呋喃基、噻吩基、吡啶基、吡咯基、N-烷基吡咯基、嘧啶基、吡嗪基、哒嗪基、咪唑基、吡唑基、三唑基、或四唑基,任选地,被1-2个独立地选自下列基团所取代:氟、 氯、溴、碘、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基和卤代C 1-4烷氧基;优选地,R 3为5-三氟甲基吡啶-2-基、或5-氯噻吩-2-基。
- 如权利要求1所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,所述R 3为未取代的C 3-8环烷基、或取代的C 3-8环烷基,这里,所述未取代的C 3-8环烷基、取代的C 3-8环烷基中的C 3-8环烷基为环丙基、环丁基、环戊基、环己基、环庚基、或环辛基;所述取代的C 3-8环烷基为1-3个独立地选自下列基团取代的环丙基、环丁基、环戊基、环己基、环庚基、或环辛基:氟、氯、溴、碘、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基、卤代C 1-4烷氧基和苯基;优选地,所述取代的C 3-8环烷基为4-叔丁基环己基、4-异丙基环己基、4-乙基环己基、4-甲基环己基、4-三氟甲基环己基、2,3-二氢-1H-茚-2-基、或2-氯环己基。
- 如权利要求12所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,所述R 3为环丙基、环戊基、环己基、环庚基、4-叔丁基环己基、4-异丙基环己基、4-乙基环己基、4-甲基环己基、4-三氟甲基环己基、2,3-二氢-1H-茚-2-基、或2-氯环己基。
- 如权利要求1所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,所述R 3为未取代的C 4-6杂环烷基或取代的C 4-6杂环烷基,这里,所述未取代的C 4-6杂环烷基或取代的C 4-6杂环烷基中C 4-6杂环烷基为四氢呋喃基、四氢吡咯基、四氢噻吩基、哌啶基、吗啉基、或哌嗪基;所述取代的C 4-6杂环烷基为被1-3个独立地选自下列基团取代的四氢呋喃基、四氢吡咯基、四氢噻吩基、哌啶基、吗啉基、或哌嗪基:氟、氯、溴、碘、C 1-4烷基、卤代C 1-4烷基、C 1-4烷氧基、卤代C 1-4烷氧基和苯基;优选地,所述取代的C 4-6杂环烷基为N-异丙基哌啶-4-基。
- 如权利要求1至14中任一项所述的化合物,或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,其中,R 4选自:氢,-C 1-3烷基-未取代的且选自氧杂和硫杂中至少一种的杂环烷基,-C 1-3烷基-取代的且选自氧杂和硫杂中至少一种的杂环烷基,-C 1-3烷基-取代螺杂环烷基,-C 1-3烷基-C(O)NR 5R 6,-C 1-3烷基-NR 7R 8,-C 1-4烷基-未取代的且选自氮杂、氧杂和硫杂中至少一种的杂芳基,和-C 1-4烷基-取代的且选自氮杂、氧杂 和硫杂中至少一种的杂芳基;这里,R 5和R 6可独立地为氢、或C 1-3烷基,或R 5和R 6及其连接N共同组成C 4-6的未取代的氮杂环烷基,或R 5和R 6及其连接N共同组成C 4-6的取代的氮杂环烷基;R 7和R 8可独立地为氢、或C 1-3烷基,或R 7和R 8及其连接N共同组成C 4-6的未取代的氮杂环烷基,或R 7和R 8及其连接N共同组成C 4-6的取代的氮杂环烷基;并规定R 4为氢时,m为0而n为1;所述取代的是指被下列一个或多个基团所取代:C1-C4烷基、C1-C4卤代烷基、C1-C4烷氧基、C1-C4卤代烷氧基、C1-C4烷酰基、C1-C4烷酰氧基、羟基、硝基、卤素、氧代和氰基;优选地,所述R 4为氢、2-(吗啉基)乙基、2-(1,1-二氧代硫代吗啉)乙基、2-(4-甲基哌嗪-1-基)乙基、2-(4-乙酰基哌嗪-1-基)乙基、2-(3-氧代哌嗪-1-基)乙基、2-(吡咯烷-1-基)乙基、2-(哌啶-1-基)乙基、2-(N,N’-二甲氨基)乙基、2-(2-氧代吡咯烷-1-基)乙基、N,N’-二甲基乙酰胺基、噁丙环-2-基甲基、或2-(2-氧杂-6-氮杂螺[3.3]庚烷-6-基)乙基;并规定R 4为氢时,m为0而n为1。
- 一种药物组合物,其包括权利要求1至16中任一项所述的化合物或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药、以及药学上可接受的载体。
- 权利要求1至16中任一项所述的化合物或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,用于药物使用。
- 一种治疗患者的μ阿片肽受体(MOPR)和κ阿片肽受体(KOPR)共同介导的或者μ阿片肽受体(MOPR)和痛敏肽/孤啡肽受体(NOPR或ORL-1受体)共同介导的失调的方法,所述方法包括对有需要的患者施用权利要求1至16中任一项所述的化合物或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,或者权利要求17所述的药物组合物。
- 一种用于调整μ阿片肽受体(MOPR)和κ阿片肽受体(KOPR)或μ阿片肽受体(MOPR)和痛敏肽/孤啡肽受体(NOPR或ORL-1受体)的方法,所述方法包括施用权利要求1至16中任一项所述的化合物或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,或者权利要求17所述的药物组合物。
- 一种用于治疗或预防患者的疼痛、焦虑、抑郁、酒精成瘾、物质滥用/依赖性的方法,所述方法包括对有需要的患者施用权利要求1至16中任一项所述的化合物或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,或者权利要求17所述的药物组合物。
- 一种用于调整μ阿片肽受体(MOPR)和κ阿片肽受体(KOPR)或 μ阿片肽受体(MOPR)和痛敏肽/孤啡肽受体(NOPR或ORL-1受体),从而治疗或预防患者的疼痛、焦虑、抑郁、酒精成瘾、物质滥用/依赖性的方法,所述方法包括对有需要的患者施用权利要求1至16中任一项所述的化合物或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,或者权利要求17所述的药物组合物。
- 权利要求1至16中任一项所述的化合物或其立体异构体、药学上可接受的盐、溶剂化物、氘代化物、代谢产物或者前药,或者权利要求17所述的药物组合物在制备治疗疼痛、焦虑、抑郁、酒精成瘾、物质滥用/依赖性的药物中的用途。
- 如权利要求23所述的用途,其中,所述的疼痛可以为急性疼痛、慢性疼痛、骨痛、关节痛、术后疼痛、肌肉疼痛、牙痛、头痛、炎性疼痛、神经性疼痛和克罗恩病相关腹痛。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22841467.8A EP4345096A1 (en) | 2021-07-14 | 2022-07-14 | Piperidine derivative, and pharmaceutical composition thereof, preparation method therefor, and use thereof |
KR1020247001875A KR20240022630A (ko) | 2021-07-14 | 2022-07-14 | 피페리딘 유도체 및 그 약물 조성물, 제조 방법과 용도 |
CN202280049762.3A CN117642389A (zh) | 2021-07-14 | 2022-07-14 | 一种哌啶衍生物及其药物组合物、制备方法和用途 |
CA3224323A CA3224323A1 (en) | 2021-07-14 | 2022-07-14 | Piperidine derivative, and pharmaceutical composition thereof, preparation method therefor, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110797657.5 | 2021-07-14 | ||
CN202110797657 | 2021-07-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023284834A1 true WO2023284834A1 (zh) | 2023-01-19 |
Family
ID=84857674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/105776 WO2023284834A1 (zh) | 2021-07-14 | 2022-07-14 | 一种哌啶衍生物及其药物组合物、制备方法和用途 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP4345096A1 (zh) |
KR (1) | KR20240022630A (zh) |
CN (2) | CN115611856A (zh) |
CA (1) | CA3224323A1 (zh) |
WO (1) | WO2023284834A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001007050A1 (en) | 1999-07-26 | 2001-02-01 | Schering Corporation | Nociceptin receptor orl-1 agonists for use in treating cough |
WO2003082333A1 (fr) * | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remede contre les troubles du sommeil |
WO2008050698A2 (en) * | 2006-10-16 | 2008-05-02 | Mitsubishi Tanabe Pharma Corporation | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
WO2017096323A1 (en) | 2015-12-02 | 2017-06-08 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
WO2017161017A1 (en) | 2016-03-15 | 2017-09-21 | The Scripps Research Institute | Signaling-biased mu opioid receptor agonists |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID29137A (id) * | 1998-07-27 | 2001-08-02 | Schering Corp | Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1 |
AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
-
2022
- 2022-07-14 CN CN202210833568.6A patent/CN115611856A/zh active Pending
- 2022-07-14 EP EP22841467.8A patent/EP4345096A1/en active Pending
- 2022-07-14 KR KR1020247001875A patent/KR20240022630A/ko active Search and Examination
- 2022-07-14 CA CA3224323A patent/CA3224323A1/en active Pending
- 2022-07-14 CN CN202280049762.3A patent/CN117642389A/zh active Pending
- 2022-07-14 WO PCT/CN2022/105776 patent/WO2023284834A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001007050A1 (en) | 1999-07-26 | 2001-02-01 | Schering Corporation | Nociceptin receptor orl-1 agonists for use in treating cough |
WO2003082333A1 (fr) * | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remede contre les troubles du sommeil |
WO2008050698A2 (en) * | 2006-10-16 | 2008-05-02 | Mitsubishi Tanabe Pharma Corporation | Agent for prophylaxis or treatment of alcohol dependence or drug dependence |
WO2017096323A1 (en) | 2015-12-02 | 2017-06-08 | Astraea Therapeutics, Llc | Piperidinyl nociceptin receptor compounds |
WO2017161017A1 (en) | 2016-03-15 | 2017-09-21 | The Scripps Research Institute | Signaling-biased mu opioid receptor agonists |
Non-Patent Citations (6)
Title |
---|
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY |
DATABASE REGISTRY ANONYMOUS : "-2(1H)-Quinazolinone, 3,4-dihydro-1-[1-[[4-(3-phenyl-2- quinoxalinyl)phenyl]methyl]-4-piperidinyl]-(CA INDEX NAME) ", XP093024591, retrieved from STN * |
PALIN, R. ; CLARK, J.K. ; EVANS, L. ; FEILDEN, H. ; FLETCHER, D. ; HAMILTON, N.M. ; HOUGHTON, A.K. ; JONES, P.S. ; MCARTHUR, D. ; : "Rapid access towards follow-up NOP receptor agonists using a knowledge based approach", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 19, no. 22, 15 November 2009 (2009-11-15), Amsterdam NL , pages 6441 - 6446, XP026703825, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2009.09.028 * |
PALIN, R. BARN, D.R. CLARK, J.K. COTTNEY, J.E. COWLEY, P.M. CROCKATT, M. EVANS, L. FEILDEN, H. GOODWIN, R.R. GRI: "Synthesis and SAR studies of 3-phenoxypropyl piperidine analogues as ORL1 (NOP) receptor agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 15, no. 3, 1 February 2005 (2005-02-01), Amsterdam NL , pages 589 - 593, XP004719973, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2004.11.049 * |
PALIN, R. BOM, A. CLARK, J.K. EVANS, L. FEILDEN, H. HOUGHTON, A.K. JONES, P.S. MONTGOMERY, B. WESTON, M.A. WISHA: "Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties", BIOORGANIC & MEDICINAL CHEMISTRY, ELSEVIER, AMSTERDAM, NL, vol. 15, no. 4, 14 January 2007 (2007-01-14), AMSTERDAM, NL, pages 1828 - 1847, XP005830444, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2006.11.030 * |
PALIN, R. ET AL.: "Structure-activity Relationships and CoMFA of N-3 Substituted Phenoxypropyl Piperidine Benzimidazol-2-one Analogues as NOP Receptor Agonists with Analgesic Properties.", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 16, 10 January 2008 (2008-01-10), XP022558519, DOI: 10.1016/j.bmc.2008.01.005 * |
Also Published As
Publication number | Publication date |
---|---|
CN117642389A (zh) | 2024-03-01 |
EP4345096A1 (en) | 2024-04-03 |
CN115611856A (zh) | 2023-01-17 |
KR20240022630A (ko) | 2024-02-20 |
CA3224323A1 (en) | 2023-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6383418B2 (ja) | 置換ベンズアミド及びその使用方法 | |
Coburn et al. | Discovery of a pharmacologically active antagonist of the two‐pore‐domain potassium channel K2P9. 1 (TASK‐3) | |
HRP20110946A2 (hr) | Enantiomeri spirooksindolskih spojeva i njihova upotreba kao terapijska sredstva | |
TW200808744A (en) | Novel diazepan derivatives | |
CN106459083B (zh) | 具有多重模式抗疼痛活性的1-氧杂-4,9-二氮杂螺十一烷化合物的酰胺衍生物 | |
PT1263729E (pt) | Compostos azacílclicos para utilização no tratamento de doenças relacionadas com a serotonina | |
CN102256983A (zh) | 螺羟吲哚化合物及其作为治疗剂的用途 | |
TW201242965A (en) | Ring-fused heterocyclic derivative | |
TW200815431A (en) | Azabenzimidazolyl compounds | |
KR20150131233A (ko) | 치환된 트리아졸로피리딘 및 이의 사용 방법 | |
US20080051441A1 (en) | Aryl Sulphonamide Modulators | |
CN103402511B (zh) | 新的苯并间二氧杂环戊烯哌啶化合物 | |
RU2302417C1 (ru) | 1-оксо-3-(1н-индол-3-ил)-1,2,3,4-тетрагидроизохинолины, способы их получения, комбинаторная библиотека и фокусированная библиотека | |
EA010312B1 (ru) | Замещенные производные 4-алкил- и 4-алканоилпиперидина и их применение в качестве антагонистов нейрокининов | |
US8138333B2 (en) | Sulfonyl-indole derivatives | |
KR20190030192A (ko) | 피라졸 유도체 화합물 및 이의 용도 | |
ES2331144T3 (es) | Derivados de isoxazolina-indol con actividad antipsicotica y ansiolitica mejorada. | |
ES2370518T3 (es) | Agentes receptores h3 de histamina, preparación y usos terapéuticos. | |
US8835422B2 (en) | Substituted imidazoheterocycle derivatives | |
JP6987746B2 (ja) | 治療用化合物及びその使用方法 | |
WO2023284834A1 (zh) | 一种哌啶衍生物及其药物组合物、制备方法和用途 | |
CN108349999A (zh) | 用于治疗药物滥用和成瘾的氧杂二氮杂螺环化合物 | |
CN103501780B (zh) | 苯并呋喃-哌啶化合物 | |
CA2754180A1 (en) | Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors | |
WO2023284833A1 (zh) | 一种螺哌啶环衍生物及其药物组合物、制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22841467 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022841467 Country of ref document: EP Ref document number: 3224323 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20247001875 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020247001875 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2022841467 Country of ref document: EP Effective date: 20231227 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |